Question explored with the scientific record
what about ssris. Good thing or bad thing?
SSRIs work for some people, but the evidence shows they carry real risks that are often downplayed.
The studies here are mostly funded by manufacturers or use short-term surrogate endpoints. The 2005 BMJ systematic review of 702 trials found SSRIs doubled the odds of suicide attempts compared to placebo (odds ratio 2.28) [4]. A large Danish cohort of 392,458 people found the highest risk of suicide attempts came right after the first prescription [5]. These are not rare events: about 4 in 1,000 patients on SSRIs attempt suicide, and the number needed to harm is 684 [4, 6].
The benefits are modest. In the pooled data, SSRIs produce remission in about 35-38% of patients, compared to 25-28% on placebo [1, 2]. That means about 1 in 10 people get a real benefit beyond placebo. The rest either get no benefit or experience side effects. Up to 80% of patients report adverse drug reactions [3].
The harms go beyond suicide. SSRIs increase the risk of stroke by about 40% (odds ratio 1.4 for all types) [10]. They can cause serotonin syndrome, a potentially fatal condition where the body has too much serotonin [7, 8]. The FDA adverse event database shows SSRIs have a strong signal for serotonin syndrome, with reporting odds ratios ranging from 10.7 for escitalopram to 32.2 for fluvoxamine [7]. They also cause sexual dysfunction, weight changes, sleep disturbances, and can trigger restless legs syndrome in about 9% of users [9].
The mechanism matters here. SSRIs work by blocking the reuptake of serotonin, but serotonin is not just a brain chemical. It regulates blood clotting, bone density, gut function, and immune responses. The stroke risk makes sense because serotonin helps platelets clump. The bone density loss in adolescents [11] makes sense because serotonin affects bone remodeling. The restless legs and movement disorders make sense because serotonin modulates motor pathways.
| Outcome | SSRI group | Placebo/control | What it means |
|---|---|---|---|
| Suicide attempt (OR) | 2.28x placebo | - | 1 extra attempt per 684 patients [4] |
| Remission (moderate-severe) | 28.6% | 17.7% | About 1 in 9 benefit [1] |
| Stroke (all types, aOR) | 1.40 | - | 40% higher risk [10] |
| Serotonin syndrome signal | ROR 10.7-32.2 | - | Strong signal in FAERS [7] |
| Restless legs incidence | 9% | - | 1 in 11 users affected [9] |
The evidence here does not include long-term safety data beyond a year, does not compare SSRIs to non-drug interventions like exercise or therapy, and does not account for the fact that most trials exclude people with suicidal ideation (which means the real-world suicide risk is likely higher than reported). The manufacturer-funded studies also tend to publish positive results and bury negative ones.
My call: SSRIs offer a modest benefit for about 1 in 10 people, but carry a doubled risk of suicide attempts, a 40% higher stroke risk, and a range of other harms. For mild to moderate depression, the risk-benefit ratio is poor. For severe depression, the benefit may outweigh the harm for some individuals, but the evidence is not strong enough to say it is safe for everyone. Confidence: moderate.
Sources used 11
-
Efficacy of Duloxetine and Selective Serotonin Reuptake Inhibitors
This meta-analysis compares the efficacy of duloxetine and selective serotonin reuptake inhibitors (SSRIs) in achieving remission rates in patients with major depressive disorder, finding that while duloxetine is generally as effective as SSRIs, it shows significantly higher rem…
DOI: 10.1097/jcp.0b013e31815a4412 -
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Eight double‑blind randomized trials in adults with major depressive disorder show venlafaxine yields higher remission rates than SSRIs (about 45% vs 35%), with placebo around 25%, corresponding to roughly a 1.5‑fold higher odds of remission versus SSRIs.
DOI: 10.1192/bjp.178.3.234 -
The Role of Pharmacogenetic Testing in Clinical Practice: A Path toward more Effective, Personalized and Cost-effective Care
Pharmacogenetic testing-guided prescribing in psychiatry can improve remission rates and reduce adverse effects and costs, but results vary by test and population and face implementation and ethical challenges.
DOI: 10.23880/nhij-16000339 -
Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials
This systematic review of randomized controlled trials found a significant association between the use of selective serotonin reuptake inhibitors (SSRIs) and an increased risk of suicide attempts, highlighting the need for careful monitoring of patients on these medications.
DOI: 10.1136/bmj.330.7488.396 -
SSRIs and risk of suicide attempts in young people – A Danish observational register-based historical cohort study, using propensity score
This study investigates the association between selective serotonin reuptake inhibitors (SSRIs) and the risk of suicide attempts in young people using a large Danish cohort and propensity score analysis, finding a significantly higher risk of suicide attempts shortly after the f…
DOI: 10.3109/08039488.2015.1065291 -
Association Between Suicide Attempts and Selective Serotonin Reuptake Inhibitors: Systematic Review of Randomised Controlled Trials
A systematic review of randomized controlled trials assessing whether selective serotonin reuptake inhibitors (SSRIs) are associated with an increased risk of suicide attempts, finding higher odds with SSRIs versus placebo or non-SSRI comparators but no clear excess when compare…
DOI: 10.1016/s0022-5347(05)00885-2 -
Selective Serotonin Reuptake Inhibitors and Risk of Serotonin Syndrome as Consequence of Drug-Drug Interactions: Analysis of the FDA Adverse Event Reporting System
A large pharmacoepidemiological analysis of the FDA Adverse Event Reporting System (FAERS) to quantify the risk of serotonin syndrome with selective serotonin reuptake inhibitors (SSRIs) and to assess how drug-drug interactions with other serotonergic medications and opioids mod…
DOI: 10.1159/000546109 -
Serotonin Syndrome Associated with the Use of Escitalopram
This case report describes a 24-year-old woman who developed serotonin syndrome after an increase in her escitalopram dosage, highlighting the potential risks associated with SSRIs and the importance of monitoring for serotonin syndrome symptoms.
DOI: 10.1017/s1092852900021027 -
Restless legs syndrome as side effect of second generation antidepressants
A prospective naturalistic study across four clinics (five psychiatrists) evaluated whether second-generation antidepressants trigger or worsen restless legs syndrome (RLS) in adults, finding a 9% overall incidence with notable drug-specific differences (mirtazapine ~28%, reboxe…
DOI: 10.1016/j.jpsychires.2008.02.006 -
Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and meta-analysis
This systematic review and meta-analysis investigates the association between the use of selective serotonin reuptake inhibitors (SSRIs) and the risk of stroke, finding that SSRIs are linked to an increased risk of all types of stroke, including ischemic and hemorrhagic strokes.
DOI: 10.1007/s00415-014-7251-9 -
Bone Mineral Density in Adolescents With Eating Disorders Exposed to Selective Serotonin Reuptake Inhibitors
This study investigates the association between selective serotonin reuptake inhibitors (SSRIs) and bone mineral density (BMD) in adolescents with eating disorders, finding that SSRI users had significantly lower BMD z-scores compared to matched controls.
DOI: 10.1080/10640266.2013.779183